for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Everest Medicines Ltd

1952.HK

Latest Trade

44.25HKD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

42.95

 - 

104.80

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
44.25
Open
--
Volume
--
3M AVG Volume
6.76
Today's High
--
Today's Low
--
52 Week High
104.80
52 Week Low
42.95
Shares Out (MIL)
298.26
Market Cap (MIL)
13,213.09
Forward P/E
-10.37
Dividend (Yield %)
--

Next Event

Everest Medicines Ltd Annual Shareholders Meeting

Latest Developments

更多

Everest Medicines Announces Submission Of NDA To Department Of Health Of HK For Xeravatm

Everest Medicines Announces A Multi-Year Research And Develop Collaboration Agreement

Abcellera And Everest Medicines Announce Multi-Target Collaboration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Everest Medicines Ltd

Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.

Industry

Biotechnology & Drugs

Contact Info

1266 West Nanjing Road

Plaza 66, Tower 1, Units 6601-6606

SHANGHAI, SHA

200040

China

http://www.everestmedicines.com/

Executive Leadership

Wei Fu

Chairman of the Board, Executive Director

Ian Ying Woo

President, Chief Financial Officer,

Kerry Levan Blanchard

Chief Executive Officer, Executive Director

Xiaofan Zhang

Chief Operating Officer, Executive Director

Frank Grams

Senior Vice President, Alliance Management and Head of Business Development in Europe

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2020

0.0K

2021(E)

0.0K
EPS (CNY)

2020

-7.064

2021(E)

-3.640
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.52
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
6.45
LT Debt To Equity (MRQ)
6.12
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up